|Bid||0.00 x 1200|
|Ask||0.00 x 1200|
|Day's range||66.60 - 67.96|
|52-week range||56.56 - 73.34|
|Beta (5Y monthly)||0.42|
|PE ratio (TTM)||16.35|
|Forward dividend & yield||2.84 (4.19%)|
|Ex-dividend date||14 Sep 2021|
|1y target est||N/A|
Earnings and other updates from bigwigs like Bristol Myers (BMY) and Moderna (MRNA) have been the biotech sector's few key highlights during the past week.
The healthcare sector is expected to witness substantial earnings growth of 17.5% in the third quarter.
With that in mind, let's look at two healthcare stocks that have performed poorly over the past year but have a chance to bounce back big: Gilead Sciences (NASDAQ: GILD) and Incyte (NASDAQ: INCY). Biotech giant Gilead Sciences is still feeling the aftereffects of a regulatory setback related to filgotinib, its potential medicine for rheumatoid arthritis. The company hoped that it would become a blockbuster product, but the U.S. Food and Drug Administration (FDA) had other plans.